{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:24:45Z","timestamp":1793658285319,"version":"4.5.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015086","name":"AOP Orphan Pharmaceuticals GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Landiolol, an ultra-fast acting super-selective beta-blocker, was investigated for the first time in Europe in a prospective clinical study for the management of supraventricular tachycardia (SVT) among paediatric patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The LANDI-PED study was a prospective, multicentre, open-label, uncontrolled phase III study aiming to investigate the efficacy, safety, and pharmacokinetics (PK) of landiolol in paediatric patients. Sixty patients in surgical and non-surgical settings aged \u22651 day to &amp;lt;18 years with SVTs of various aetiologies received landiolol as a continuous intravenous infusion starting with 5\u2005\u03bcg\/kg\/min titrated up to 40\u2005\u03bcg\/kg\/min depending on heart rate (HR) reduction for up to a maximum of 24\u2005h. The primary endpoint was restoration of normal sinus rhythm (NSR) within 210\u2005min of infusion start. The primary endpoint was achieved in 15 (25.0%) patients. A total of 24 (40.0%) patients achieved a HR reduction of at least 20% within 210\u2005min of landiolol infusion. A significant HR reduction was observed within minutes post-infusion, with a mean (\u00b1SD) reduction after 210\u2005min of \u221213.2 (\u00b111.5)% (P &amp;lt; 0.0001) in the overall population. By infusion end, 51.7% of patients achieved HR reduction of at least 20% from baseline and\/or NSR conversion. The PK characteristics were consistent with the known profile of landiolol among adults. The most common adverse drug reaction was hypotension (10%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and\/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>EU Clinical Trial Register; EudraCT Number: 2015-001129-17.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euaf025","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:04:11Z","timestamp":1739491451000},"source":"Crossref","is-referenced-by-count":9,"title":["Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED)"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-573X","authenticated-orcid":false,"given":"Ina","family":"Michel-Behnke","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Division of Paediatric Cardiology, Medical University of Vienna, General Hospital Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-9860","authenticated-orcid":false,"given":"Matthias","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology and Intensive Care Medicine, Paediatric Heart Centre Giessen, University Hospital Giessen and Marburg GmbH , Giessen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-4647","authenticated-orcid":false,"given":"Brigitte","family":"Stiller","sequence":"additional","affiliation":[{"name":"Department of Congenital Heart Disease and Paediatric Cardiology, Faculty of Medicine, Heart Centre Freiburg University, University of Freiburg , Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3907-8350","authenticated-orcid":false,"given":"Thomas","family":"Kriebel","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Paediatric Cardiology, Westpfalz Hospital , Kaiserslautern ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-0748","authenticated-orcid":false,"given":"Majed","family":"Kanaan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, Children\u2019s Heart Centre Aachen, University Hospital RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-6133","authenticated-orcid":false,"given":"L\u00e1szl\u00f3","family":"K\u00f6rnyei","sequence":"additional","affiliation":[{"name":"Gottsegen National Cardiovascular Centre, Paediatric Heart Centre , Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mai","sequence":"additional","affiliation":[{"name":"Paediatrics 3\u2013Centre for Congenital Heart Defects Stuttgart, Paediatric Intensive Care, Pulmonology and Allergology, Stuttgart Hospital\u2013Olgahospital , Stuttgart ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9803-5532","authenticated-orcid":false,"given":"Roman","family":"Gebauer","sequence":"additional","affiliation":[{"name":"Clinic for Paediatric Cardiology, Heart Centre Leipzig GmbH , Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8727-2257","authenticated-orcid":false,"given":"Jens","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Intensive Care, Kepler University Clinic, Kepler University , Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-7490","authenticated-orcid":false,"given":"Ferran","family":"Roses-Noguer","sequence":"additional","affiliation":[{"name":"Paediatric Cardiology Department, University Hospital Vall d\u2019 Hebron , Barcelona ,","place":["Spain"]},{"name":"Honorary Paediatric EP Consultant, Royal Brompton and Harefield Hospital, London, UK and European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9600-8618","authenticated-orcid":false,"given":"Martin","family":"Unger","sequence":"additional","affiliation":[{"name":"AOP Orphan Pharmaceuticals GmbH , Leopold-Ungar-Platz 2, 1190 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7755-5981","authenticated-orcid":false,"given":"Stefanie","family":"Schlager","sequence":"additional","affiliation":[{"name":"AOP Orphan Pharmaceuticals GmbH , Leopold-Ungar-Platz 2, 1190 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-5173","authenticated-orcid":false,"given":"Charu","family":"Charu","sequence":"additional","affiliation":[{"name":"AOP Orphan Pharmaceuticals GmbH , Leopold-Ungar-Platz 2, 1190 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Klade","sequence":"additional","affiliation":[{"name":"AOP Orphan Pharmaceuticals GmbH , Leopold-Ungar-Platz 2, 1190 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Krejcy","sequence":"additional","affiliation":[{"name":"AOP Orphan Pharmaceuticals GmbH , Leopold-Ungar-Platz 2, 1190 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Ackerl","sequence":"additional","affiliation":[{"name":"AOP Orphan Pharmaceuticals GmbH , Leopold-Ungar-Platz 2, 1190 Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Krumpl","sequence":"additional","affiliation":[{"name":"Board of Directors, AOP Health International Management AG , Ruggell ,","place":["Liechtenstein"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2025030423505618700_euaf025-B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cjcpc.2021.09.001","article-title":"Medical management of infants with supraventricular tachycardia: results from a registry and review of the literature","volume":"1","author":"Wei","year":"2022","journal-title":"CJC Pediatr Congenit Heart Dis"},{"key":"2025030423505618700_euaf025-B2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1024\/0040-5930.58.2.94","article-title":"Diagnosis and treatment of common pediatric supraventricular tachycardias","volume":"58","author":"Bauersfeld","year":"2001","journal-title":"Ther Umsch"},{"key":"2025030423505618700_euaf025-B3","first-page":"46","article-title":"Management of neonatal supraventricular tachycardias; a single center experience","volume":"3","author":"Epcacan","year":"2019","journal-title":"Eurasian J Med Investig"},{"key":"2025030423505618700_euaf025-B4","doi-asserted-by":"crossref","first-page":"e112484","DOI":"10.5812\/compreped.112484","article-title":"Successful management of an atrioventricular nodal re-entrant tachycardia in a neonate: a case report","volume":"12","author":"Hosseini","year":"2021","journal-title":"J Compr Ped"},{"key":"2025030423505618700_euaf025-B5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.5152\/TurkArchPediatr.2022.22099","article-title":"Common supraventricular and ventricular arrhythmias in children","volume":"57","author":"Kafal\u0131","year":"2022","journal-title":"Turk Arch Pediatr"},{"key":"2025030423505618700_euaf025-B6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.46747\/cfp.6912839","article-title":"Management of acute supraventricular tachycardia in children","volume":"69","author":"Abbasi","year":"2023","journal-title":"Can Fam Physician"},{"key":"2025030423505618700_euaf025-B7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3928\/00904481-20141022-13","article-title":"Supraventricular tachycardia in infancy and childhood","volume":"43","author":"Spearman","year":"2014","journal-title":"Pediatr Ann"},{"key":"2025030423505618700_euaf025-B8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4103\/0974-2700.66525","article-title":"Emergency diagnosis and management of pediatric arrhythmias","volume":"3","author":"Hanash","year":"2010","journal-title":"J Emerg Trauma Shock"},{"key":"2025030423505618700_euaf025-B9","doi-asserted-by":"crossref","first-page":"euad155","DOI":"10.1093\/europace\/euad155","article-title":"Advancing the science of management of arrhythmic disease in children and adult congenital heart disease patients within the last 25 years","volume":"25","author":"Paul","year":"2023","journal-title":"Europace"},{"key":"2025030423505618700_euaf025-B10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00246-022-02853-9","article-title":"Antiarrhythmic medication in neonates and infants with supraventricular tachycardia","volume":"43","author":"Bruder","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"2025030423505618700_euaf025-B11","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/europace\/eut082","article-title":"Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-arrhythmia working group joint consensus statement","volume":"15","author":"Brugada","year":"2013","journal-title":"Europace"},{"key":"2025030423505618700_euaf025-B12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/PCC.0000000000000229","article-title":"Comparative effectiveness of digoxin and propranolol for supraventricular tachycardia in infants","volume":"15","author":"Hornik","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"2025030423505618700_euaf025-B13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00380-013-0377-3","article-title":"Novel use of the ultra-short-acting intravenous beta1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure","volume":"29","author":"Adachi","year":"2014","journal-title":"Heart Vessels"},{"key":"2025030423505618700_euaf025-B14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2710.2011.01315.x","article-title":"Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection","volume":"37","author":"Nakano","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2025030423505618700_euaf025-B15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s11748-011-0841-x","article-title":"Efficacy of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer","volume":"59","author":"Nojiri","year":"2011","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2025030423505618700_euaf025-B16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5492\/wjccm.v4.i3.251","article-title":"Landiolol, an ultra-short-acting beta1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis","volume":"4","author":"Okajima","year":"2015","journal-title":"World J Crit Care Med"},{"key":"2025030423505618700_euaf025-B17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1253\/circj.CJ-11-1332","article-title":"Landiolol, an ultra-short-acting beta(1)-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study)","volume":"76","author":"Sakamoto","year":"2012","journal-title":"Circ J"},{"key":"2025030423505618700_euaf025-B18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40256-013-0035-2","article-title":"The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting beta1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study","volume":"13","author":"Taenaka","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025030423505618700_euaf025-B19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1510\/icvts.2009.212837","article-title":"Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose","volume":"9","author":"Wariishi","year":"2009","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2025030423505618700_euaf025-B20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jclinane.2014.07.003","article-title":"Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study","volume":"27","author":"Xiao","year":"2015","journal-title":"J Clin Anesth"},{"key":"2025030423505618700_euaf025-B21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1248\/cpb.40.1462","article-title":"Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101","volume":"40","author":"Iguchi","year":"1992","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2025030423505618700_euaf025-B22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00540-007-0558-2","article-title":"Cardioprotective effect and mechanism of action of landiolol on the ischemic reperfused heart","volume":"21","author":"Kimura-Kurosawa","year":"2007","journal-title":"J Anesth"},{"key":"2025030423505618700_euaf025-B23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1253\/circj.CJ-19-0661","article-title":"Open-label two-dose pilot study of landiolol for the treatment of atrial fibrillation\/atrial flutter in Caucasian patients","volume":"84","author":"Stix","year":"2019","journal-title":"Circ J"},{"key":"2025030423505618700_euaf025-B24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/pharmaceutics16040517","article-title":"An overview of the pharmacokinetics and pharmacodynamics of landiolol (an ultra-short acting \u03b21 selective antagonist) in atrial fibrillation","volume":"16","author":"Floria","year":"2024","journal-title":"Pharmaceutics"},{"key":"2025030423505618700_euaf025-B25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00540-008-0640-4","article-title":"Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts","volume":"22","author":"Ikeshita","year":"2008","journal-title":"J Anesth"},{"key":"2025030423505618700_euaf025-B26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-016-2176-0","article-title":"Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group","volume":"73","author":"Krumpl","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025030423505618700_euaf025-B27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/FJC.0000000000000554","article-title":"Pharmacokinetics and pharmacodynamics of low-, intermediate-, and high-dose landiolol and esmolol during long-term infusion in healthy Whites","volume":"71","author":"Krumpl","year":"2018","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025030423505618700_euaf025-B28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/CRD.0000000000000555","article-title":"Landiolol: an ultra-short-acting beta-blocker","volume":"32","author":"Rao","year":"2024","journal-title":"Cardiol Rev"},{"key":"2025030423505618700_euaf025-B29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.26502\/fccm.92920291","article-title":"The superselective \u03b21-blocker landiolol enhances inotropy of endogenous and exogenous catecholamines in acute heart failure","volume":"6","author":"Feuerstein","year":"2022","journal-title":"Cardiol Cardiovasc Med"},{"key":"2025030423505618700_euaf025-B30","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00228-023-03584-3","article-title":"Mechanisms of landiolol-mediated positive inotropy in critical care settings","volume":"79","author":"Chalkias","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2025030423505618700_euaf025-B31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1254\/jphs.11202FP","article-title":"Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts","volume":"118","author":"Shibata","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"2025030423505618700_euaf025-B32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.116.232884","article-title":"Comparison of the \u03b2-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions","volume":"359","author":"Nasrollahi-Shirazi","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"2025030423505618700_euaf025-B33"},{"key":"2025030423505618700_euaf025-B34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025030423505618700_euaf025-B35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC guidelines for the management of patients with supraventricular tachycardia. The task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur Heart J"},{"key":"2025030423505618700_euaf025-B36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/joa3.12078","article-title":"Efficacy and safety of cardioversion with continuous landiolol infusion for atrial tachyarrhythmia in an inflammatory state caused by volvulus in a child with TARP syndrome and postoperative tetralogy of Fallot","volume":"34","author":"Miyamoto","year":"2018","journal-title":"J Arrhythm"},{"key":"2025030423505618700_euaf025-B37","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PEC.0000000000001008","article-title":"Successful management of fulminant Guillain-Barre syndrome and its complications","volume":"34","author":"Kamei","year":"2018","journal-title":"Pediatr Emerg Care"},{"key":"2025030423505618700_euaf025-B38","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/europace\/eut044","article-title":"Landiolol hydrochloride infusion for treatment of junctional ectopic tachycardia in post-operative paediatric patients with congenital heart defect","volume":"15","author":"Saiki","year":"2013","journal-title":"Europace"},{"key":"2025030423505618700_euaf025-B39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11748-012-0141-0","article-title":"Landiolol for junctional ectopic tachycardia refractory to amiodarone after pediatric cardiac surgery","volume":"61","author":"Hasegawa","year":"2013","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2025030423505618700_euaf025-B40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1047951115000244","article-title":"Efficacy of landiolol for the treatment of junctional ectopic tachycardia resulting from sepsis","volume":"26","author":"Oka","year":"2016","journal-title":"Cardiol Young"},{"key":"2025030423505618700_euaf025-B41","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.athoracsur.2013.01.057","article-title":"Effects of landiolol hydrochloride on intractable tachyarrhythmia after pediatric cardiac surgery","volume":"95","author":"Tokunaga","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"2025030423505618700_euaf025-B42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00540-015-2119-4","article-title":"Effects of landiolol on refractory tachyarrhythmia after total cavopulmonary connection: a retrospective, observational, cohort study","volume":"30","author":"Miyake","year":"2016","journal-title":"J Anesth"},{"key":"2025030423505618700_euaf025-B43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/PCC.0000000000001573","article-title":"Landiolol hydrochloride rapidly controls junctional ectopic tachycardia after pediatric heart surgery","volume":"19","author":"Yoneyama","year":"2018","journal-title":"Pediatr Crit Care Med"},{"key":"2025030423505618700_euaf025-B44","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s00246-021-02653-7","article-title":"Safety and efficacy of landiolol hydrochloride in children with tachyarrhythmia of various etiologies","volume":"42","author":"Ashida","year":"2021","journal-title":"Pediatr Cardiol"},{"key":"2025030423505618700_euaf025-B45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ehf2.14202","article-title":"Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension","volume":"10","author":"Schroeder","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2025030423505618700_euaf025-B46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1253\/circj.CJ-21-0967","article-title":"Control of heart rate in infant and child tachyarrhythmia with reduced cardiac function using landiolol (HEARTFUL)\u2014results of a prospective, multicenter, uncontrolled clinical study","volume":"87","author":"Sagawa","year":"2022","journal-title":"Circ J"},{"key":"2025030423505618700_euaf025-B47","volume-title":"A Short-Acting Selective \u03b21 Blocker, Onoact\u00ae for Intravenous Infusion 50 mg\/150mg: Approved for Additional Indication of Tachyarrhythmia in Pediatric Patients with low Cardiac Function in Japan","author":"Ono Pharmaceutical Co Ltd","year":"2022"},{"key":"2025030423505618700_euaf025-B48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FJC.0000000000000495","article-title":"Pharmacodynamic and -kinetic behavior of low-, intermediate-, and high-dose landiolol during long-term infusion in Whites","volume":"70","author":"Krumpl","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025030423505618700_euaf025-B49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jjcc.2019.05.012","article-title":"A prospective observational survey on landiolol in atrial fibrillation\/atrial flutter patients with chronic heart failure\u2014AF-CHF landiolol survey","volume":"74","author":"Yamashita","year":"2019","journal-title":"J Cardiol"},{"key":"2025030423505618700_euaf025-B50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/joa3.12282","article-title":"Junctional ectopic tachycardia in infants and children","volume":"36","author":"Kylat","year":"2020","journal-title":"J Arrhythm"},{"key":"2025030423505618700_euaf025-B51","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/apc.apc_35_21","article-title":"Diagnosis and management of junctional ectopic tachycardia in children","volume":"14","author":"Sasikumar","year":"2021","journal-title":"Ann Pediatr Cardiol"},{"key":"2025030423505618700_euaf025-B52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1253\/circj.CJ-12-1618","article-title":"Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting \u03b21-selective blocker landiolol with digoxin (J-Land study)","volume":"77","author":"Nagai","year":"2013","journal-title":"Circ J"},{"key":"2025030423505618700_euaf025-B53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.joa.2015.09.002","article-title":"Practical applicability of landiolol, an ultra-short-acting \u03b21-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction","volume":"32","author":"Wada","year":"2016","journal-title":"J Arrhythm"},{"key":"2025030423505618700_euaf025-B54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","article-title":"Efficacy and safety of landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Kakihana","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025030423505618700_euaf025-B55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00392-023-02295-0","article-title":"Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials","volume":"113","author":"Perrett","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2025030423505618700_euaf025-B56","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3390\/jcm13102951","article-title":"Landiolol for treatment of new-onset atrial fibrillation in critical care: a systematic review","volume":"13","author":"Levy","year":"2024","journal-title":"J Clin Med"},{"key":"2025030423505618700_euaf025-B57","first-page":"e48507","article-title":"Amiodarone and adenosine for pediatric supraventricular tachycardia: a systematic review","volume":"15","author":"Guerra Toro","year":"2023","journal-title":"Cureus"},{"key":"2025030423505618700_euaf025-B58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00246-006-1162-1","article-title":"The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias","volume":"27","author":"Adamson","year":"2006","journal-title":"Pediatr Cardiol"},{"key":"2025030423505618700_euaf025-B59","first-page":"302","article-title":"Optimizing pediatric esmolol dosing using computerized practitioner order entry","volume":"19","author":"Chao","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2025030423505618700_euaf025-B60","first-page":"1531","article-title":"Phase 1 study of ONO-1101, a new ultra short-acting beta 1-blocking agent in healthy volunteers","volume":"16","author":"Nakashima","year":"2000","journal-title":"J Clin Ther Med"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euaf025\/61870644\/euaf025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/2\/euaf025\/61870644\/euaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/27\/2\/euaf025\/61870644\/euaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:51:18Z","timestamp":1741132278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euaf025\/8011531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euaf025","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]},"article-number":"euaf025"}}